Medication use in infants with severe bronchopulmonary dysplasia admitted to United States children's hospitals

J Perinatol. 2019 Sep;39(9):1291-1299. doi: 10.1038/s41372-019-0415-9. Epub 2019 Jun 21.

Abstract

Objective: To identify the number of cumulative medication exposures and most frequently used medications in infants with severe BPD.

Study design: We performed a retrospective cohort study in infants with severe BPD admitted to United States children's hospitals. We measured cumulative medication exposures in individual subjects and between-center variation after adjustment for infant characteristics. We then identified the specific medications and therapeutic classes with the highest rates of use.

Results: In 3252 subjects across 43 hospitals, we identified a median (interquartile range) of 30 (17-45) cumulative medication exposures per infant. The adjusted mean number of medication exposures varied between centers (p < 0.0001), with a range of 22-50. Diuretics and furosemide were the most frequently prescribed therapeutic class and specific medication for the management of severe BPD.

Conclusions: Infants with severe BPD are exposed to alarming number of medications of unclear efficacy and safety, with marked variation between center.

MeSH terms

  • Bronchopulmonary Dysplasia / drug therapy*
  • Drug Utilization / statistics & numerical data*
  • Female
  • Gestational Age
  • Hospitalization
  • Hospitals, Pediatric
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Intensive Care Units, Neonatal
  • Male
  • Retrospective Studies
  • United States